Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

Who May Qualify: - Male or female, 18 to 75 years of age - Body mass index between 18.0 and 38.0 kg/m² - Fulfills classification criteria for SSc according to ACR/EULAR 2013 criteria - Has diffuse cutaneous SSc, defined as mRSS \>0 over at least one skin area proximal to the elbows and/or knees, in addition to acral fibrosis - Has had SSc (defined as the first non-Raynaud's phenomenon (RP) symptom or sign attributed to SSc) for ≤7 years - mRSS ≥15 and ≤45 at screening. Additional requirements for participants ≥2 years to ≤7 years from SSc onset and RNA Polymerase III antibody positive - FVC \>50% predicted - Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥40% predicted (corrected for hemoglobin) Who Should NOT Join This Trial: - Has any of the following complications: - Left ventricular failure - Pulmonary arterial hypertension - Renal crisis within previous 6 months - Gastrointestinal dysmotility within previous 3 months - Digital ischemia with gangrene, amputation, or unscheduled hospitalization within previous 3 months - Current rheumatic disease other than SSc that could interfere with assessment of SSc - Lung disease requiring continuous oxygen therapy - Evidence or suspicion of active or latent tuberculosis - Active Crohn's Disease or ulcerative colitis Always talk to your doctor about whether this trial is right for you.